Par’s Off-Label Plea Deal Includes Clawback For Execs’ Pay In Case Of Future Misconduct
This article was originally published in The Pink Sheet Daily
Executive Summary
Par will pay $45 million for off-label promotion of Megace ES and enter a corporate integrity agreement that restricts incentive compensation for sales reps; the firm also drops its suit against FDA and removes descriptions of conversations with government officials from its court filings.
You may also be interested in...
FDA First Amendment Litigation: Will Amarin Case Break The Log Jam?
Courts have issued mixed rulings in cases challenging FDA restrictions on drug promotion, but with oral arguments set for July 7, Amarin’s suit could provide a definitive answer on what companies can tell physicians.
Par Enters Generic Injectable Market Via JHP Buy
The generics maker is expanding its portfolio of reformulations through the acquisition of privately-held JHP in a deal worth $490 million, expected to close in short order.
J&J Risperdal Off-Label Settlement Includes Exec Pay Recoupment Provision
Janssen subsidiary pleads guilty as part of $2.2 billion deal that also requires audits of sales rep compensation.